Will the UK–US pharmaceuticals deal really cause 229,000 excess deaths? A critical appraisal
Journal of Comparative Effectiveness Research · 2026-11 · 15 (11)
DOI: 10.57264/cer-2026-0186 ↗Kurz gefasst
Editorial in der Zeitschrift Journal of Comparative Effectiveness Research, 2026-11. Verfasst von Sreeram V Ramagopalan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Pharmaceutical Medicine Research, King's College London, London, SE1 9NH, UK. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centre for Pharmaceutical Medicine Research, King's College London, London, SE1 9NH, UK.
- Koios Enterprises & Consulting, Denver, CO, USA.
Zitieren
APA
Ramagopalan, S. V., & Ryan, M. L. (2026). Will the UK–US pharmaceuticals deal really cause 229,000 excess deaths? A critical appraisal. Journal of Comparative Effectiveness Research, 15(11). https://doi.org/10.57264/cer-2026-0186
Vancouver
Ramagopalan SV, Ryan ML. Will the UK–US pharmaceuticals deal really cause 229,000 excess deaths? A critical appraisal. Journal of Comparative Effectiveness Research. 2026;15(11). doi:10.57264/cer-2026-0186
BibTeX
@article{Ramagopalan2026,
author = {Ramagopalan, Sreeram V and Ryan, Michael L},
title = {Will the UK–US pharmaceuticals deal really cause 229,000 excess deaths? A critical appraisal},
journal = {Journal of Comparative Effectiveness Research},
year = {2026},
volume = {15},
number = {11},
doi = {10.57264/cer-2026-0186}
}
EUVIMED